- Home
- TJGC vs CLGN Comparison
TJGC vs CLGN Comparison
Compare TJGC & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | CLGN |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Advertising | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 18.4M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | TJGC | CLGN |
|---|---|---|
| Price | $0.85 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 68.6K | ★ 76.0K |
| Earning Date | 02-23-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,916,631.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | $85.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 280.77 |
| 52 Week Low | $0.63 | $0.66 |
| 52 Week High | $54.91 | $4.98 |
Technical Indicators
Market Signals| Indicator | TJGC | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.